Last 12 months
Inside the activity.
0 purchase rows · 34 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 3 |
| Dec 2025 | 0 | 3 |
| Jan 2026 | 0 | 1 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 4 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 7 |
| Jun 2026 | 0 | 9 |
| Jul 2026 | 0 | 3 |
| Aug 2026 | 0 | 2 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 28, 2021 Filed Apr 30, 2021 20:07 UTC |
Hagen HeidiDirector
|
GrantRestricted Stock Unit · Derivative | 2,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-21-001209 · primary_01.xml · derivative · entry 4 Hagen Heidi · CIK 0001585084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,600 Underlying: Common Stock · 2,600 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of Vericel Corporation. F6 · derivative.exercise_date: These RSUs vest 100% on the earlier of April 28, 2022 or the date of the first Annual Meeting of Stockholders following April 28, 2021. F4 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| April 28, 2021 Filed Apr 30, 2021 20:07 UTC |
Hagen HeidiDirector
|
GrantStock Option (right to buy) · Derivative | 6,500 | $0.00 Strike: $63.22 | $0.00 |
DisclosureSEC source: 0001593968-21-001209 · primary_01.xml · derivative · entry 3 Hagen Heidi · CIK 0001585084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,500 Underlying: Common Stock · 6,500 shares Expires 2031-04-28 F5 · derivative.exercise_date: The option vests over a 1-year period, in equal monthly increments, contingent upon continued service to the Company. Read SEC document |
| April 28, 2021 Filed Apr 30, 2021 20:07 UTC |
Hagen HeidiDirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-21-001209 · primary_01.xml · derivative · entry 2 Hagen Heidi · CIK 0001585084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of Vericel Corporation. F3 · derivative.exercise_date: These RSUs vest 100% on the earlier of April 29, 2021 or the date of the first Annual Meeting of Stockholders following April 29, 2020. The first Annual Meeting of Stockholders occurred on April 28, 2021. F4 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| April 28, 2021 Filed Apr 30, 2021 20:07 UTC |
Hagen HeidiDirector
|
Exercise / conversionCommon Stock | 1,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001593968-21-001209 · primary_01.xml · nonDerivative · entry 1 Hagen Heidi · CIK 0001585084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units granted to the Reporting Person on April 29, 2020. Read SEC document |
| April 28, 2021 Filed Apr 30, 2021 20:06 UTC |
ZERBE ROBERT L MDDirector
|
GrantRestricted Stock Unit · Derivative | 2,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-21-001208 · primary_01.xml · derivative · entry 4 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,600 Underlying: Common Stock · 2,600 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of Vericel Corporation. F7 · derivative.exercise_date: These RSUs vest 100% on the earlier of April 28, 2022 or the date of the first Annual Meeting of Stockholders following April 28, 2021. Vested shares will be delivered to the Reporting Person following termination of service on the Company's Board of Directors. F5 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| April 28, 2021 Filed Apr 30, 2021 20:06 UTC |
ZERBE ROBERT L MDDirector
|
GrantStock Option (right to buy) · Derivative | 6,500 | $0.00 Strike: $63.22 | $0.00 |
DisclosureSEC source: 0001593968-21-001208 · primary_01.xml · derivative · entry 3 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,500 Underlying: Common Stock · 6,500 shares Expires 2031-04-28 F6 · derivative.exercise_date: The option vests over a 1-year period, in equal monthly increments, contingent upon continued service to the Company. Read SEC document |
| April 28, 2021 Filed Apr 30, 2021 20:06 UTC |
ZERBE ROBERT L MDDirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001593968-21-001208 · primary_01.xml · derivative · entry 2 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of Vericel Corporation. F2 · price: Upon the vesting of RSUs granted to the Reporting Person on April 29, 2020, the Reporting Person deferred the receipt of 1,750 shares of Common Stock and instead received 1,750 shares of Phantom Stock pursuant to the Company's Non-Employee Directors' Deferred Compensation Program. F4 · derivative.exercise_date: These RSUs vest 100% on the earlier of April 29, 2021 or the date of the first Annual Meeting of Stockholders following April 29, 2020. The first Annual Meeting of Stockholders occurred on April 28, 2021. F5 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| April 28, 2021 Filed Apr 30, 2021 20:06 UTC |
ZERBE ROBERT L MDDirector
|
Exercise / conversionCommon Stock | 1,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001593968-21-001208 · primary_01.xml · nonDerivative · entry 1 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Restricted Stock Units (RSUs) converted to phantom stock units and are deferred under the Company's Non-Employee Directors' Deferred Compensation Program. The units will be payable only in shares of Common Stock after the end of the Reporting Person's service on the Company's Board of Directors. F2 · price: Upon the vesting of RSUs granted to the Reporting Person on April 29, 2020, the Reporting Person deferred the receipt of 1,750 shares of Common Stock and instead received 1,750 shares of Phantom Stock pursuant to the Company's Non-Employee Directors' Deferred Compensation Program. Read SEC document |
| April 28, 2021 Filed Apr 30, 2021 20:03 UTC |
Wotton Paul KDirector
|
GrantRestricted Stock Unit · Derivative | 2,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-21-001207 · primary_01.xml · derivative · entry 4 Wotton Paul K · CIK 0001300997 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,600 Underlying: Common Stock · 2,600 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of Vericel Corporation. F6 · derivative.exercise_date: These RSUs vest 100% on the earlier of April 28, 2022 or the date of the first Annual Meeting of Stockholders following April 28, 2021. F4 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| April 28, 2021 Filed Apr 30, 2021 20:03 UTC |
Wotton Paul KDirector
|
GrantStock Option (right to buy) · Derivative | 6,500 | $0.00 Strike: $63.22 | $0.00 |
DisclosureSEC source: 0001593968-21-001207 · primary_01.xml · derivative · entry 3 Wotton Paul K · CIK 0001300997 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,500 Underlying: Common Stock · 6,500 shares Expires 2031-04-28 F5 · derivative.exercise_date: The option vests over a 1-year period, in equal monthly increments, contingent upon continued service to the Company. Read SEC document |
| April 28, 2021 Filed Apr 30, 2021 20:03 UTC |
Wotton Paul KDirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-21-001207 · primary_01.xml · derivative · entry 2 Wotton Paul K · CIK 0001300997 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of Vericel Corporation. F3 · derivative.exercise_date: These RSUs vest 100% on the earlier of April 29, 2021 or the date of the first Annual Meeting of Stockholders following April 29, 2020. The first Annual Meeting of Stockholders occurred on April 28, 2021. F4 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| April 28, 2021 Filed Apr 30, 2021 20:03 UTC |
Wotton Paul KDirector
|
Exercise / conversionCommon Stock | 1,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001593968-21-001207 · primary_01.xml · nonDerivative · entry 1 Wotton Paul K · CIK 0001300997 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units granted to the Reporting Person on April 29, 2020. Read SEC document |
| April 28, 2021 Filed Apr 30, 2021 20:02 UTC |
GILMAN STEVEN CDirector
|
GrantStock Option (right to buy) · Derivative | 6,500 | $0.00 Strike: $63.22 | $0.00 |
DisclosureSEC source: 0001593968-21-001206 · primary_01.xml · derivative · entry 4 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,500 Underlying: Common Stock · 6,500 shares Expires 2031-04-28 F6 · derivative.exercise_date: The option vests over a 1-year period, in equal monthly increments, contingent upon continued service to the Company. Read SEC document |
| April 28, 2021 Filed Apr 30, 2021 20:02 UTC |
GILMAN STEVEN CDirector
|
GrantRestricted Stock Unit · Derivative | 2,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-21-001206 · primary_01.xml · derivative · entry 3 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,600 Underlying: Common Stock · 2,600 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of Vericel Corporation. F5 · derivative.exercise_date: These RSUs vest 100% on the earlier of April 28, 2022 or the date of the first Annual Meeting of Stockholders following April 28, 2021. F4 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| April 28, 2021 Filed Apr 30, 2021 20:02 UTC |
GILMAN STEVEN CDirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-21-001206 · primary_01.xml · derivative · entry 2 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of Vericel Corporation. F3 · derivative.exercise_date: These RSUs vest 100% on the earlier of April 29, 2021 or the date of the first Annual Meeting of Stockholders following April 29, 2020. The first Annual Meeting of Stockholders occurred on April 28, 2021. F4 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| April 28, 2021 Filed Apr 30, 2021 20:02 UTC |
GILMAN STEVEN CDirector
|
Exercise / conversionCommon Stock | 1,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001593968-21-001206 · primary_01.xml · nonDerivative · entry 1 GILMAN STEVEN C · CIK 0001379970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units granted to the Reporting Person on April 29, 2020. Read SEC document |
| April 19, 2021 Filed Apr 20, 2021 20:15 UTC |
Colangelo DominickDirector · President and CEO
|
Exercise / conversionStock Option (right to buy) · Derivative | 7,563 | $0.00 Strike: $25.80 | $0.00 |
DisclosureSEC source: 0001593968-21-001129 · primary_01.xml · derivative · entry 5 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,938 Underlying: Common Stock · 7,563 shares Expires 2023-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: These options, representing the right to purchase 55,001 shares, became exercisable on March 6, 2014, the first anniversary of the date of grant, with 25% vesting and the remaining 75% vesting in equal monthly installments over three years thereafter, contingent upon continued service to the Company. Read SEC document |
| April 19, 2021 Filed Apr 20, 2021 20:15 UTC |
Colangelo DominickDirector · President and CEO
|
SaleCommon Stock | 16,250 | $57.46 | $933,725.00 |
DisclosureSEC source: 0001593968-21-001129 · primary_01.xml · nonDerivative · entry 4 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,973 F1 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| April 19, 2021 Filed Apr 20, 2021 20:15 UTC |
Colangelo DominickDirector · President and CEO
|
SaleCommon Stock | 14,760 | $57.92 | $854,899.20 |
DisclosureSEC source: 0001593968-21-001129 · primary_01.xml · nonDerivative · entry 3 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,223 F1 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| April 19, 2021 Filed Apr 20, 2021 20:15 UTC |
Colangelo DominickDirector · President and CEO
|
Exercise / conversionCommon Stock | 7,563 | $25.80 | $195,125.40 |
DisclosureSEC source: 0001593968-21-001129 · primary_01.xml · nonDerivative · entry 2 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,983 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: The Reporting Person has elected to exercise and hold these shares at this time. F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| April 19, 2021 Filed Apr 20, 2021 20:15 UTC |
Colangelo DominickDirector · President and CEO
|
SaleCommon Stock | 8,990 | $59.13 | $531,578.70 |
DisclosureSEC source: 0001593968-21-001129 · primary_01.xml · nonDerivative · entry 1 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,420 F1 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. F2 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| March 31, 2021 Filed Apr 1, 2021 20:15 UTC |
Mara Joseph Anthony JrChief Financial Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 4,000 | $55.55 | $222,200.00 |
DisclosureSEC source: 0001593968-21-001040 · primary_01.xml · derivative · entry 3 Mara Joseph Anthony Jr · CIK 0001841148 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 4,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of Vericel Corporation. F4 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on January 25, 2021. The remaining RSUs will vest in quarterly installments on June 30, 2021, September 30, 2021, and December 31, 2021, respectively. F5 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| March 31, 2021 Filed Apr 1, 2021 20:15 UTC |
Mara Joseph Anthony JrChief Financial Officer
|
Tax withholdingCommon Stock | 1,178 | $55.55 | $65,437.90 |
DisclosureSEC source: 0001593968-21-001040 · primary_01.xml · nonDerivative · entry 2 Mara Joseph Anthony Jr · CIK 0001841148 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,822 F2 · shares: These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of Restricted Stock Units. Read SEC document |
| March 31, 2021 Filed Apr 1, 2021 20:15 UTC |
Mara Joseph Anthony JrChief Financial Officer
|
Exercise / conversionCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-21-001040 · primary_01.xml · nonDerivative · entry 1 Mara Joseph Anthony Jr · CIK 0001841148 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on January 25, 2021. The remaining RSUs will vest in quarterly installments on June 30, 2021, September 30, 2021, and December 31, 2021, respectively. Read SEC document |
| March 30, 2021 Filed Mar 30, 2021 20:50 UTC |
Colangelo DominickDirector · President and CEO
|
Exercise / conversionStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $25.80 | $0.00 |
DisclosureSEC source: 0001593968-21-001029 · primary_01.xml · derivative · entry 6 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,501 Underlying: Common Stock · 7,500 shares Expires 2023-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These options, representing the right to purchase 55,001 shares, became exercisable on March 6, 2014, the first anniversary of the date of grant, with 25% vesting and the remaining 75% vesting in equal monthly installments over three years thereafter, contingent upon continued service to the Company. Read SEC document |
| March 30, 2021 Filed Mar 30, 2021 20:50 UTC |
Colangelo DominickDirector · President and CEO
|
Exercise / conversionCommon Stock | 7,500 | $25.80 | $193,500.00 |
DisclosureSEC source: 0001593968-21-001029 · primary_01.xml · nonDerivative · entry 5 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,050 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: The Reporting Person has elected to exercise and hold these shares at this time. Read SEC document |
| March 30, 2021 Filed Mar 31, 2021 20:17 UTC |
Hopper Jonathan MarkChief Medical Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 8,438 | $0.00 Strike: $10.95 | $0.00 |
DisclosureSEC source: 0001593968-21-001030 · primary_01.xml · derivative · entry 9 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,298 Underlying: Common Stock · 8,438 shares Expires 2028-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options, representing the right to purchase 135,000 shares, became exercisable on August 20, 2019, the first anniversary of the date of grant, with 25% vesting and the remaining 75% vesting in equal quarterly installments over three years thereafter, contingent upon continued service to the Company. Read SEC document |
| March 30, 2021 Filed Mar 31, 2021 20:17 UTC |
Hopper Jonathan MarkChief Medical Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $10.95 | $0.00 |
DisclosureSEC source: 0001593968-21-001030 · primary_01.xml · derivative · entry 8 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,736 Underlying: Common Stock · 20,000 shares Expires 2028-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options, representing the right to purchase 135,000 shares, became exercisable on August 20, 2019, the first anniversary of the date of grant, with 25% vesting and the remaining 75% vesting in equal quarterly installments over three years thereafter, contingent upon continued service to the Company. Read SEC document |
| March 30, 2021 Filed Mar 31, 2021 20:17 UTC |
Hopper Jonathan MarkChief Medical Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $10.95 | $0.00 |
DisclosureSEC source: 0001593968-21-001030 · primary_01.xml · derivative · entry 7 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,736 Underlying: Common Stock · 5,000 shares Expires 2028-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options, representing the right to purchase 135,000 shares, became exercisable on August 20, 2019, the first anniversary of the date of grant, with 25% vesting and the remaining 75% vesting in equal quarterly installments over three years thereafter, contingent upon continued service to the Company. Read SEC document |
| March 30, 2021 Filed Mar 31, 2021 20:17 UTC |
Hopper Jonathan MarkChief Medical Officer
|
SaleCommon Stock | 11,104 | $51.84 | $575,644.68 |
DisclosureSEC source: 0001593968-21-001030 · primary_01.xml · nonDerivative · entry 6 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,480 F1 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. Read SEC document |
| March 30, 2021 Filed Mar 31, 2021 20:17 UTC |
Hopper Jonathan MarkChief Medical Officer
|
Exercise / conversionCommon Stock | 20,000 | $10.95 | $219,000.00 |
DisclosureSEC source: 0001593968-21-001030 · primary_01.xml · nonDerivative · entry 5 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,584 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 30, 2021 Filed Mar 31, 2021 20:17 UTC |
Hopper Jonathan MarkChief Medical Officer
|
SaleCommon Stock | 1,820 | $51.00 | $92,820.00 |
DisclosureSEC source: 0001593968-21-001030 · primary_01.xml · nonDerivative · entry 4 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,584 F1 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. Read SEC document |
| March 30, 2021 Filed Mar 31, 2021 20:17 UTC |
Hopper Jonathan MarkChief Medical Officer
|
Exercise / conversionCommon Stock | 8,438 | $10.95 | $92,396.10 |
DisclosureSEC source: 0001593968-21-001030 · primary_01.xml · nonDerivative · entry 3 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,404 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 30, 2021 Filed Mar 31, 2021 20:17 UTC |
Hopper Jonathan MarkChief Medical Officer
|
SaleCommon Stock | 5,000 | $50.56 | $252,805.00 |
DisclosureSEC source: 0001593968-21-001030 · primary_01.xml · nonDerivative · entry 2 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,966 F1 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. Read SEC document |
| March 30, 2021 Filed Mar 31, 2021 20:17 UTC |
Hopper Jonathan MarkChief Medical Officer
|
Exercise / conversionCommon Stock | 5,000 | $10.95 | $54,750.00 |
DisclosureSEC source: 0001593968-21-001030 · primary_01.xml · nonDerivative · entry 1 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,966 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 29, 2021 Filed Mar 30, 2021 20:50 UTC |
Colangelo DominickDirector · President and CEO
|
SaleCommon Stock | 13,125 | $50.94 | $668,587.50 |
DisclosureSEC source: 0001593968-21-001029 · primary_01.xml · nonDerivative · entry 4 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,550 F1 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. Read SEC document |
| March 29, 2021 Filed Mar 30, 2021 20:50 UTC |
Colangelo DominickDirector · President and CEO
|
SaleCommon Stock | 10,313 | $50.93 | $525,241.09 |
DisclosureSEC source: 0001593968-21-001029 · primary_01.xml · nonDerivative · entry 3 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,675 F1 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. Read SEC document |
| March 29, 2021 Filed Mar 30, 2021 20:50 UTC |
Colangelo DominickDirector · President and CEO
|
SaleCommon Stock | 15,552 | $51.09 | $794,551.68 |
DisclosureSEC source: 0001593968-21-001029 · primary_01.xml · nonDerivative · entry 2 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,988 F1 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. Read SEC document |
| March 29, 2021 Filed Mar 30, 2021 20:50 UTC |
Colangelo DominickDirector · President and CEO
|
SaleCommon Stock | 1,010 | $51.36 | $51,873.60 |
DisclosureSEC source: 0001593968-21-001029 · primary_01.xml · nonDerivative · entry 1 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,540 F1 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. Read SEC document |
| March 19, 2021 Filed Mar 22, 2021 20:19 UTC |
Rubino Alan LDirector
|
Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $45.20 | $0.00 |
DisclosureSEC source: 0001593968-21-000988 · primary_01.xml · derivative · entry 2 Rubino Alan L · CIK 0001340228 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2021-03-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options, representing the right to purchase a total of 5,000 shares, became exercisable in equal annual installments over three years, contingent upon continued service to the Company, with the first vesting date on March 21, 2012, which was one year after the date on which the option was granted. Read SEC document |
| March 19, 2021 Filed Mar 22, 2021 20:19 UTC |
Rubino Alan LDirector
|
Exercise / conversionCommon Stock | 5,000 | $45.20 | $226,000.00 |
DisclosureSEC source: 0001593968-21-000988 · primary_01.xml · nonDerivative · entry 1 Rubino Alan L · CIK 0001340228 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,644 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The Reporting Person has elected to exercise and hold these shares at this time. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 21:15 UTC |
Colangelo DominickDirector · President and CEO
|
Exercise / conversionStock Option (right to buy) · Derivative | 15,925 | $0.00 Strike: $2.75 | $0.00 |
DisclosureSEC source: 0001593968-21-000706 · primary_01.xml · derivative · entry 10 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,700 Underlying: Common Stock · 15,925 shares Expires 2027-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: These options, representing the right to purchase a total of 210,000 shares, became exercisable in equal quarterly installments, contingent upon continued service to the Company, with the first vesting date on May 8, 2017, which was one quarter after the date on which the option was granted. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 21:15 UTC |
Colangelo DominickDirector · President and CEO
|
Exercise / conversionStock Option (right to buy) · Derivative | 6,805 | $0.00 Strike: $7.20 | $0.00 |
DisclosureSEC source: 0001593968-21-000706 · primary_01.xml · derivative · entry 9 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 293,195 Underlying: Common Stock · 6,805 shares Expires 2028-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These options, representing the right to purchase a total of 300,000 shares, became exercisable in equal quarterly installments, contingent upon continued service to the Company, with the first vesting date on May 7, 2018, which was one quarter after the date on which the option was granted. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 21:15 UTC |
Colangelo DominickDirector · President and CEO
|
Exercise / conversionStock Option (right to buy) · Derivative | 5,625 | $0.00 Strike: $2.65 | $0.00 |
DisclosureSEC source: 0001593968-21-000706 · primary_01.xml · derivative · entry 8 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,125 Underlying: Common Stock · 5,625 shares Expires 2027-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 6.25% of these options, representing the right to purchase a total of 90,000 shares, became exercisable immediately on May 22, 2017. An additional 6.25% became exercisable on August 8, 2017 and continue to vest in equal quarterly installments from August 8, 2017, contingent upon the continued service to the Company. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 21:15 UTC |
Colangelo DominickDirector · President and CEO
|
SaleCommon Stock | 8,692 | $48.01 | $417,302.92 |
DisclosureSEC source: 0001593968-21-000706 · primary_01.xml · nonDerivative · entry 7 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,550 F1 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 21:15 UTC |
Colangelo DominickDirector · President and CEO
|
SaleCommon Stock | 27,500 | $48.06 | $1,321,650.00 |
DisclosureSEC source: 0001593968-21-000706 · primary_01.xml · nonDerivative · entry 6 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,242 F1 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 21:15 UTC |
Colangelo DominickDirector · President and CEO
|
Exercise / conversionCommon Stock | 15,925 | $2.75 | $43,793.75 |
DisclosureSEC source: 0001593968-21-000706 · primary_01.xml · nonDerivative · entry 5 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 243,742 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 21:15 UTC |
Colangelo DominickDirector · President and CEO
|
Exercise / conversionCommon Stock | 6,805 | $7.20 | $48,996.00 |
DisclosureSEC source: 0001593968-21-000706 · primary_01.xml · nonDerivative · entry 4 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,817 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 21:15 UTC |
Colangelo DominickDirector · President and CEO
|
Exercise / conversionCommon Stock | 5,625 | $2.65 | $14,906.25 |
DisclosureSEC source: 0001593968-21-000706 · primary_01.xml · nonDerivative · entry 3 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,012 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2021 Filed Mar 2, 2021 21:15 UTC |
Colangelo DominickDirector · President and CEO
|
SaleCommon Stock | 2,260 | $48.78 | $110,242.80 |
DisclosureSEC source: 0001593968-21-000706 · primary_01.xml · nonDerivative · entry 2 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,387 F1 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.